Business
Citius Oncology Ships First International Order of LYMPHIR™ to Europe
Citius Oncology, Inc. ("Citius Oncology") (Nasdaq: CTOR), an oncology‑focused biopharmaceutical company and majority‑owned subsidiary of Citius Pharmaceuticals, Inc. ("Citius Pharma") (Nasdaq: CTXR), today announced the initial shipment of LYMPHIR™ (denileukin diftitox-cxdl) to Europe through one of its regional distribution partners, marking an important milestone in expanding access to the therapy for patients outside the United States. LYMPHIR will be made available to eligible patients throu
About this update from Citius Pharmaceuticals, Inc.
[{"type":"text","content":"Order fulfilment expands international patient access to LYMPHIR following initial U.S. launch","length":94,"tagName":"p","attribs":{}},{"type":"text","content":"Distribution by regional partners through Named Patient Programs in specific international markets","length":98,"tagName":"p","attribs":{}},{"type":"text","content":"CRANFORD, N.J., April 29, 2026 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology") (Nasdaq: CTOR), an oncology‑focused biopharmaceutical company and majority‑owned subsidiary of Citius Pharmaceuticals, Inc. ("Citius Pharma") (Nasdaq: CTXR), today announced the initial shipment of LYMPHIR™ (denileukin diftitox-cxdl) to Europe through one of its regional distribution partners, marking an important milestone in expanding access to the therapy for patients outside the United States. LYMPHIR will be made available to eligible patients through Named Patient Programs (NPPs) in accordance with local regulations in each country.","length":653,"tagName":"p"},{"type":"image","alt":"Citius Oncology logo (PRNewsfoto/Citius Oncology, Inc.)","displaySize":"","headline":null,"caption":"Citius Oncology logo (PRNewsfoto/Citius Oncology, Inc.)","className":"","disableSlideshowImg":false,"size":{"original":{"width":357,"height":400,"url":"https://media.zenfs.com/en/prnewswire.com/92b6ee873ab0a518804912f9102afc89"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/zp3Rh_eVDszG6FJ1Viq6iw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTc5MA--/https://media.zenfs.com/en/prnewswire.com/92b6ee873ab0a518804912f9102afc89","width":357,"height":400}},"href":"https://mma.prnewswire.com/media/2588198/Citius_Oncology_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"The initiation of European distribution represents a strategic step in the Company's broader effort to extend access to LYMPHIR for patients with limited treatment options, while continuing to prioritize disciplined and targeted market entry.","length":246,"tagName":"p"},{"type":"text","content":""Reaching this milestone underscores our commitment to ensuring that patients in need can access LYMPHIR beyond the United States," said Leonard Mazur, Chairman and Chief Executive Officer of Citius Oncology. "Through our distribution partners, we are enabling physicians to request LYMPHIR for appropriate patients via establis...